xFOREST Therapeutics (Headquarter: Kamigyo-ku, Kyoto, Japan; President and CEO: Shunichi Kashida; hereinafter, xFOREST) announced today that it has reached an agreement with Daiichi Sankyo Company, Limited (Headquarter: Chuo-ku, Tokyo, Japan; hereinafter, Daiichi Sankyo) on a drug discovery collaboration to target RNA structures in multiple diseases.
Under the agreement, xFOREST will provide its proprietary FOREST technologies, a suite of large-scale parallel analysis platforms, to promote systematic small molecule drug discovery research targeting RNA structures. Daiichi Sankyo will have exclusive rights to develop and commercialize RNA-targeted small molecules identified from the collaboration.
About xFOREST Therapeutics
xFOREST Therapeutics Co., Ltd. is a Kyoto-based biotechnology company engaged in the research and development of RNA-targeted small-molecule medicines. Building on its proprietary RNA structure analysis technology, xFOREST discovers selective small molecules for RNA targets that protein-first discovery cannot reach, and advances them into drug programs with partners.